Connect with us

Hi, what are you looking for?

Wednesday, Oct 5, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.

The weed wire

Cannabics Pharmaceuticals files patent for cannabinoid colon cancer treatment

The highly potent but non psychoactive compound has anti-tumour properties, company says

Cannabics Pharmaceuticals files patent for using weed to fight colon cancer

A cannabinoid drug developer has filed a patent for its colon cancer treatment. 

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) filed a U.S. provisional patent for its “Composition and Method for Treating Colon Cancer with Cannabinoids,” on Wednesday, the company said in a statement. 

The formula uses a potent cocktail of non-psychoactive cannabinoids, which allow people to go through the treatment without ever feeling high. The cannabinoids have anti-tumour properties, Cannabics said, which could be used as a possible adjunct or stand-alone therapy to fight colon cancer. 

The novel formulation was discovered while the company tested how cannabis could be used to fight gastrointestinal cancers. 

In April, the company said it completed a preclinical trial that used a high dose of the the cannabinoid cannabidivarin (CBDV) and cannabigerolic acid (CBGA) to fight colon cancer.

Read more: Cannabics Pharmaceuticals developing cannabinoid colon cancer treatment

The two cannabinoids have anti-tumour properties, the company said — but only when used against certain cancers. 

So, no silver bullet for the world’s deadliest disease has been discovered yet. But cannabis legalization in countries like Canada has helped reduce stigma around the drug, and helped attract research money to test how weed can be used in novel ways.

The company is American, but does most of its work at its research facility in Tel Aviv, Israel. Cannabics is licensed by the Israeli Ministry of Health to do scientific and clinical research on how cannabinoids can be used to fight cancer. 

According to the company website, it hopes to one day use cannabinoids to personalize cancer treatments and therapies.

“By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy,” it says. 

Read more: US FDA gives rare designation to THC cancer drug in clinical trials 

Read more: Tilray back first human study on cannabis in breast cancer patients

Top image: press photo

 

michelle@mugglehead.com

@missmishelle

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like

Business

The company expects to start exporting early next year

International

Innovative new studies in the Middle East receive approval from Israeli Ministry of Health

Business

This is the largest medical cannabis pharmacy worldwide, according to InterCure

Business

The deals expand the firm's distribution and retail in the country